Maxim Group Releases a Buy Rating on Milestone Scientific

By Carrie Williams

In a report released today, Anthony Vendetti from Maxim Group assigned a Buy rating to Milestone Scientific (NYSE: MLSS), with a price target of $4. The company’s shares closed yesterday at $1.36.

Vendetti wrote:

“3Q17 revenue of $2.85M, down 10.4% y/y, was slightly above our estimate of $2.74M.”

According to TipRanks.com, Vendetti is a 5-star analyst with an average return of 15.5% and a 62.1% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Xtant Medical Holdings, Syneron Medical Ltd, and Viveve Medical Inc.

Milestone Scientific has an analyst consensus of Moderate Buy, with a price target consensus of $4.

The company has a one-year high of $2.15 and a one-year low of $1.08. Currently, Milestone Scientific has an average volume of 51.64K.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MLSS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Milestone Scientific, Inc. engages in pioneering proprietary, innovative technological systems and solutions for the medical and dental markets. It develops, manufactures, markets and sells computer controlled system for the improved and painless delivery of local anesthetic.